Pharmacokinetic Modeling Suggests Current THC Driving Limits May Not Work for Oral Cannabis Users
A new pharmacokinetic model for oral cannabis showed that a 1 ng/mL blood THC driving limit produces too many false positives, while 2 and 5 ng/mL limits remain inconclusive without better data linking blood levels to impairment.
Quick Facts
What This Study Found
Using data from 10 published studies, researchers built a model simulating THC blood levels in frequent and occasional users after oral doses from 2.5 to 100 mg. The 1 ng/mL per se limit was the least effective due to high false positive risk. The 2 and 5 ng/mL limits could not be validated because there is insufficient data connecting specific blood THC levels to actual driving impairment after oral consumption.
Key Numbers
Model built from 10 published studies. Simulated doses: 2.5 mg to 100 mg oral THC. Three per se limits evaluated: 1, 2, and 5 ng/mL. The 1 ng/mL limit showed the highest false positive risk across both user types.
How They Did This
Semi-mechanistic population pharmacokinetic model developed from 10 published studies of intravenous or oral cannabis administration. Simulated THC and metabolite concentrations across a range of doses in frequent and occasional users to evaluate existing per se driving limits.
Why This Research Matters
With edibles and oral cannabis products growing in popularity, driving laws based on blood THC levels need to account for how oral consumption produces very different blood level patterns than smoking. Current laws were largely designed around inhalation data.
The Bigger Picture
Cannabis-impaired driving laws remain one of the most contentious policy areas. This study highlights a fundamental problem: existing blood THC thresholds were developed primarily from inhalation data and may be inappropriate for the growing population of oral cannabis users.
What This Study Doesn't Tell Us
Model was built from published study data, not new clinical trials. Pharmacodynamic (impairment) data for oral cannabis remains scarce. Simulations may not capture all real-world variability in absorption and metabolism.
Questions This Raises
- ?What blood THC level actually correlates with impaired driving after oral consumption?
- ?Should driving laws use different thresholds for different consumption methods?
- ?Are there better biomarkers than blood THC for assessing impairment?
Trust & Context
- Key Stat:
- The 1 ng/mL THC driving limit had the highest false positive risk across all simulated scenarios
- Evidence Grade:
- Moderate: well-constructed pharmacokinetic model from multiple studies, but limited by lack of pharmacodynamic (impairment) validation data.
- Study Age:
- 2025 study.
- Original Title:
- Evaluation of Cannabis Per Se Laws: A Semi-Mechanistic Pharmacometrics Model for Quantitative Characterization of THC and Metabolites in Oral Users.
- Published In:
- Journal of clinical pharmacology, 65(5), 535-549 (2025)
- Authors:
- Li, Peizhi(2), An, Guohua(2)
- Database ID:
- RTHC-06936
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Why do current THC driving limits not work well for edible users?
Oral cannabis produces different blood THC patterns than smoking. Existing per se limits were designed around inhalation data and may flag edible users long after any impairment has passed.
Is there a good blood THC level that reliably indicates impairment?
Not yet. The study found insufficient data linking specific blood THC concentrations to actual driving impairment after oral consumption, which is a major gap in current law.
Read More on RethinkTHC
Cite This Study
https://rethinkthc.com/research/RTHC-06936APA
Li, Peizhi; An, Guohua. (2025). Evaluation of Cannabis Per Se Laws: A Semi-Mechanistic Pharmacometrics Model for Quantitative Characterization of THC and Metabolites in Oral Users.. Journal of clinical pharmacology, 65(5), 535-549. https://doi.org/10.1002/jcph.6181
MLA
Li, Peizhi, et al. "Evaluation of Cannabis Per Se Laws: A Semi-Mechanistic Pharmacometrics Model for Quantitative Characterization of THC and Metabolites in Oral Users.." Journal of clinical pharmacology, 2025. https://doi.org/10.1002/jcph.6181
RethinkTHC
RethinkTHC Research Database. "Evaluation of Cannabis Per Se Laws: A Semi-Mechanistic Pharm..." RTHC-06936. Retrieved from https://rethinkthc.com/research/li-2025-evaluation-of-cannabis-per
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.